Actelion Tracleer Label Revision: No Efficacy For Congestive Heart Failure
Executive Summary
Actelion's Tracleer (bosentan) is "not effective" in treating congestive heart failure, new labeling for the endothelin receptor antagonist states
You may also be interested in...
Actelion Tracleer Promotion Cited By FDA For False Statements On CHF
FDA is directing Actelion to stop promoting Tracleer for unapproved use in the treatment of congestive heart failure
Actelion Will Launch Tracleer Through Closed Distribution System
Actelion's launch of the pulmonary hypertension drug Tracleer will include converting 200 patients in an ongoing, open-label trial to its closed commercial distribution system, the company told analysts Nov. 21
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011